(Adds details, background)
GENEVA, Jan 11 (Reuters) - The World Health Organization
(WHO) on Monday redoubled pleas for vaccine makers to provide
COVID-19 shots to its COVAX programme for poor nations, as an
adviser said hopes of starting inoculations by February hinge on
access to supplies.
The COVAX facility, backed by the WHO, GAVI the vaccine
alliance, and the Coalition for Epidemic Preparedness
Innovations, has raised $6 billion so far, and ordered 2 billion
doses of COVID-19 vaccines with options on 1 billion more.
With nations including China, the United States, Israel and
others dominating early deliveries, however, the WHO fears scant
remaining stockpiles could leave 92 lower- and lower-middle
income nations out in the cold when it comes to vaccinating
their medical workers in the COVAX programme's initial round.
"We expect, and we have strong confidence that we should be
able to begin vaccinating in February in these countries," WHO
senior adviser Bruce Aylward told a press conference on Monday.
"But we cannot do that on our own. We require the
cooperation of vaccine manufacturers to prioritise deliveries to
the COVAX facility," he said.
More than 40 countries have begun vaccinating against
COVID-19 with a growing number of shots, from Pfizer and
BioNTech, Moderna, AstraZeneca, as
well as vaccines developed in Russia and China.
"All of that vaccination, or virtually all, was in
high-income or middle-income countries so far," Aylward said.
"We have got to see vaccines going into arms in lower and
lower-middle income countries.
According to Reuters data, China has administered the most
shots, at about 9 million, followed by 6.7 million in the United
States and 1.8 million in Israel. (https://tmsnrt.rs/2LK8dK4)
Aylward held out optimism that limited COVAX vaccinations in
poor nations could even start this month.
"But again, that requires the cooperation of a lot of other
players," he said. "Right now, we have an inequitable
situation."
(Reporting by Emma Farge, Stephanie Nebehay and John Miller;
Writing by Peter Graff;
Editing by Alison Williams)
Astrazeneca (AZN)
